{
    "clinical_study": {
        "@rank": "99218", 
        "arm_group": {
            "arm_group_label": "Metastatic castrate-resistant prostate cancer", 
            "description": "This single-arm observational study will be conducted at The University of North Carolina (UNC) at Chapel Hill, and four institutions in the Prostate Cancer Clinical Trials Consortium (PCCTC): Memorial Sloan-Kettering Cancer Center; Johns Hopkins; University of Washington; and Oregon Health & Science University.  UNC is the coordinating center.  The target enrollment is 500 patients, with at least 300 experiencing \"moderate or worse\" pain intensity at baseline, defined as a score of \u22654, the preferred regulatory cutoff. Targeted enrollment will be used to help ensure that 60% of the patients have at least moderate pain at baseline."
        }, 
        "brief_summary": {
            "textblock": "This is a single-arm observational longitudinal study in of patients with metastatic\n      castrate-resistant prostate cancer designed to assess the longitudinal trajectory of pain\n      and other symptoms."
        }, 
        "brief_title": "Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer", 
        "completion_date": {
            "#text": "December 2023", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Castrate-Resistant Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a single-arm observational longitudinal study in of patients with metastatic\n      castrate-resistant prostate cancer designed to assess the longitudinal trajectory of pain\n      and other symptoms.  The study aims to address several key methodological questions that\n      will inform the design of future clinical trials with symptom endpoints in this population,\n      including: the definition of \"clinically meaningful\" pain; criteria for concluding a\n      clinically meaningful pain reduction; criteria for concluding clinically meaningful pain\n      progression; reliable methods quantifying analgesic use (given that \"equianalgesic tables\"\n      and \"point scoring systems\" are generally considered unreliable by pain researchers and\n      regulatory agencies , , ); ideal recall periods for pain questions; tradeoffs of different\n      frequencies of symptom reporting; symptom trajectories over time; and associations of pain\n      scores with other metrics used in prostate cancer research (imaging, PSA values, circulating\n      tumor cells, etc)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The subject must be \u2265 18 years old on the day of consent.\n\n          -  The subject is able to understand written and spoken English\n\n          -  The patient must have histologically or cytologically confirmed prostate\n             adenocarcinoma.\n\n          -  The subject must have castration-resistant prostate cancer (CRPC)\n\n          -  The subject must have metastatic disease involving bone, seen on radiographic imaging\n             (bone scan, CT scan, PET scan, or MRI).\n\n          -  The subject must be in a castrate state (e.g., currently receiving androgen\n             deprivation therapy or have had an orchiectomy).\n\n          -  The subject must be starting any line treatment post-androgen\n             deprivation/antiandrogen therapy, such as the following: chemotherapy (e.g.,\n             docetaxel, paclitaxel, carboplatin, cabazitaxel, or mitoxantrone); abiraterone\n             acetate; MDV3100; ketoconazole; sipuleucel-T; Radium 223.\n\n          -  The subject owns or has regular access to a telephone (cellular or land line).\n\n          -  The subject is willing and able to self-report pain and analgesic use via an\n             automated telephone system.\n\n          -  The subject is willing and able to provide informed consent.\n\n        Exclusion Criteria:\n\n          -  The subject has small cell or predominantly neuroendocrine differentiated prostate\n             tumor."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Oncology clinic"
            }
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02008058", 
            "org_study_id": "LCCC 1231", 
            "secondary_id": "12-2562"
        }, 
        "intervention": {
            "arm_group_label": "Metastatic castrate-resistant prostate cancer", 
            "description": "Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks.  Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study.  Patients will remain on study for up to 26 months (slightly longer than the expected median survival in this population based on data from docetaxel, abiraterone, and MDV3100 pivotal phase 3 trials).", 
            "intervention_name": "Telephone survey system", 
            "intervention_type": "Behavioral", 
            "other_name": "Webcore telephone survey system"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Metastatic Castrate-Resistant Prostate Cancer", 
            "LCCC 1231", 
            "Lineberger Comprehensive Cancer Center", 
            "UNC Lineberger", 
            "Prostate Cancer", 
            "Pain"
        ], 
        "lastchanged_date": "March 27, 2014", 
        "link": [
            {
                "description": "Lineberger Comprehensive Cancer Center website", 
                "url": "http://unclineberger.org/"
            }, 
            {
                "description": "National Cancer Institute (NCI) website", 
                "url": "http://www.cancer.gov/"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21231"
                    }, 
                    "name": "Johns Hopkins University"
                }, 
                "investigator": {
                    "last_name": "Michael Carducci, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "Lineberger Comprehensive Cancer Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Ethan Basch, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Matthew Milowsky, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Oregon Health and Science University"
                }, 
                "investigator": {
                    "last_name": "Tomasz Beer Beer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": ", MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "University of Washington"
                }, 
                "investigator": {
                    "last_name": "Celestia Higano, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "LCCC 1231: Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer", 
        "overall_contact": {
            "email": "sara_raboin@med.unc.edu", 
            "last_name": "Sara Raboin, PhD", 
            "phone": "(919) 966-4432"
        }, 
        "overall_contact_backup": {
            "email": "gayle_grigson@med.unc.edu", 
            "last_name": "Gayle Grigson, RN", 
            "phone": "(919) 966-4432"
        }, 
        "overall_official": {
            "affiliation": "University of North Carolina", 
            "last_name": "Ethan Basch, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Determine the proportion of pain palliation responders and the proportion experiencing pain progression will be presented along with 95% confidence intervals.", 
            "measure": "Proportion of pain palliation responders", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02008058"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Determine the clinical significance of pain score changes.  Pain score changes will be compared with each of the following \"anchors\": patient rating of change in pain, as well as changes in patient functional status, analgesic use, and various measures of disease status (imaging, PSA, circulating tumor cells). ROC curves derived using logistic regression analyses will be used to characterize the association between  change in pain scores and clinically important improvement (defined by anchor variables).", 
                "measure": "Clinical significance of pain score changes", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Descriptive statistics, including Kaplan-Meier, will be used to report findings for the proportion of asymptomatic men who ultimately develop pain, the median time until asymptomatic men develop pain, the median time until men with pain experience pain progression, and the median time until men with pain experience pain palliation.", 
                "measure": "Prevalence and trajectory of pain progression and pain palliation", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }, 
            {
                "description": "Three different approaches to calculating a single value to represent total analgesic use will be compared: 1) equianalgesic tables published in guidelines of the National Comprehensive Cancer Network (NCCN) which convert various drugs and doses to \"morphine equivalents\"; 2) point scoring systems used in prior pivotal phase 3 trials based on the World Health Organization analgesic ladder in which lower points are assigned to weaker agents/doses and vice versa for stronger agents/doses; and 3) individual drug dose quantification, a dose recently suggested by the FDA but never empirically evaluated, in which each analgesic is considered individually and a 25% change in dose is considered an increase or decrease for each.", 
                "measure": "Quantifying analgesic medication use", 
                "safety_issue": "No", 
                "time_frame": "26 months"
            }, 
            {
                "description": "Seven consecutive days of reporting a pain item with a 24-hour recall item will be compared with a single administration of a pain item with a 7-day recall, in order to evaluate if the latter alone is sufficient for measuring pain.", 
                "measure": "Frequency of pain reporting", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Identify the web-avidity of patients by summarizing patients' responses to questionnaire items about their use of internet and email.", 
                "measure": "Web-avidity of patients", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "source": "UNC Lineberger Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Department of Defense", 
                    "agency_class": "U.S. Fed"
                }, 
                {
                    "agency": "Memorial Sloan-Kettering Cancer Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Johns Hopkins University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Washington", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Oregon Health and Science University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "UNC Lineberger Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}